May 5, 2020 / 5:58 AM / 25 days ago

BRIEF-SynAct: Initial Data From First Part Of Phase II Study Within RA

May 5 (Reuters) - SynAct Pharma AB:

* SYNACT PRESENTS INITIAL DATA FROM THE FIRST PART OF THE PHASE II STUDY WITHIN RA AND GIVES AN UPDATE ON ITS PROGRESSION

* FIRST OF TWO TESTED DOSES (50 MG) IDENTIFIED TO BE SAFE AND WELL-TOLERATED

* BLINDED REVIEW REVEALED THAT PATIENTS IN STUDY FORM TWO GROUPS BASED ON CHANGES IN THEIR CLINICAL DISEASE ACTIVITY INDEX

* NOW INITIATES NEXT DOSE LEVEL (100 MG)

* DESPITE COVID-19 UNCERTAINTIES, SYNACT PHARMA EXPECTS THAT CASH ON HAND AND ADDITIONAL FUNDS FROM EXERCISE OF OPTIONS (TO2) IN JULY 2020, WILL BE SUFFICIENT TO SECURE CONTINUED CLINICAL DEVELOPMENT OF AP1189 Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below